๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Tianjin
Clinical trial register · China

Clinical Trials in Tianjin, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Tianjin 25 Xingtai 4 Nanchang 3 Guangzhou 2 Kunming 2
Narrow the registerReset
Recruitment status
Phase
Site location
Tianjin25 Xingtai4 Nanchang3 Guangzhou2 Kunming2
All 8 locations
Target enrolment
to

Trials with a site in Tianjin

25 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Phase II Trial of Tunlametinib in Patients With NRAS Mutant Non-melanoma Refractory Solid Tumors
NCT07170293Solid Cancers
Tianjin Medical University Second Hospital
Phase 2
15
Tianjin
2027-08-31
Not yet open
Active Surveillance Versus Adjuvant Intravesical Chemotherapy in Liquid Biopsy-Defined Low-Shedding Intermediate-Risk NMIBC
NCT07749924Bladder Cancer, Non-Muscle-Invasive Bladder Cancer (NMIBC)
Tianjin Medical University Second Hospital
Not applicable
670
Daqing, Nanchang, Tianjin
2026-08-10
Recruiting
Phase II Study of Becotatug Vedotin Plus Pucotenlimab for Advanced Refractory Solid Tumors With EGFR-Positive
NCT07712029Advanced Refractory Solid Tumors, EGFR Gene Overexpression
Tianjin Medical University Second Hospital
Phase 2
32
Tianjin
2026-08-01
Not yet open
Bladder-Sparing Treatment With Disitamab Vedotin and Toripalimab With or Without Pelvic Lymph Node Dissection in Bladder Cancer
NCT07756008Bladder Urothelial Carcinoma, Muscle-invasive Bladder Cancer, Bladder Cancer
Tianjin Medical University Second Hospital
Phase 2/3
114
Tianjin
2026-08-01
Not yet open
Is Prolonged Systemic Immunotherapy Necessary After Achieving Tumor-free Status in Patients With Extensive Transurethrally Unresectable Very-high-risk NMIBC?
NCT07625527Bladder (Urothelial, Transitional Cell) Cancer, Non Muscle Invasive Bladder Cancer
Tianjin Medical University Second Hospital
Phase 2
120
Tianjin, Xingtai
2026-05-30
Recruiting
Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer
NCT07475403Bladder Cancer, Liquid Biopsy, Immunotherapy
Tianjin Medical University Second Hospital
Phase 2
53
Tianjin, Xingtai
2026-03-16
Recruiting
Using Liquid Biopsy Testing to Identify, Monitor, Predict Recurrence in Urothelial Carcinoma
NCT07441499Urothelial Carcinoma (UC), Bladder (Urothelial, Transitional Cell) Cancer, Liquid Biopsy
Tianjin Medical University Second Hospital
Observational
300
Tianjin
2026-03
Active, closed
Multimodal Prediction of Postoperative Prognosis After Partial Nephrectomy for Endophytic Renal Cell Carcinoma
NCT07697417Renal Cell Carcinoma, Kidney Neoplasms, Endophytic Renal Tumor, Postoperative Renal Function
Tianjin Medical University Second Hospital
Observational
406
Tianjin
2026-01-01
Recruiting
Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer
NCT07233252Renal Pelvic Carcinoma, Tislelizumab, PD-1 Inhibitor, Kidney-sparing
Tianjin Medical University Second Hospital
Phase 2
35
Tianjin
2025-11-25
Recruiting
Guiding Value of Urinary Tumor DNA Testing in Repeat Transurethral Resection of Non-Muscle-Invasive Bladder Cancer
NCT07187635Bladder Cancer, Liquid Biopsy, Repeat Transurethral Resection of Bladder Tumor
Tianjin Medical University Second Hospital
Not applicable
196
Nanchang, Guangzhou, Xingtai, Kunming, Shanghai, Tianjin
2025-09-28
Recruiting
Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC)
NCT07179783Prostate Cancer (Adenocarcinoma), Prostate Cancer Metastatic Castration-Resistant, Prostate Adenocarcinoma With Neuroendocrine Differentiation
Tianjin Medical University Second Hospital
Phase 2
28
Tianjin
2025-09-22
Recruiting
Guiding Value of Urinary Tumor DNA Testing in Cystoscopy for High-Risk/Very High-Risk Non-Muscle-Invasive Bladder Cancer
NCT07180212Bladder Cancer, Liquid Biopsy, Cystoscopy
Tianjin Medical University Second Hospital
Not applicable
360
Xingtai, Guangzhou, Haerbin, Kunming, Nanchang, Tianjin
2025-09-20
Recruiting
Radical Nephroureterectomy With vs Without Template Lymph Node Dissection in High-Risk Upper Tract Urothelial Carcinoma (T-LND UTUC)
NCT07321210Upper Tract Urothelial Carcinoma, Lymph Node Dissection
Tianjin Medical University Second Hospital
Not applicable
150
Tianjin
2025-09-01
Recruiting
Radical Nephrectomy With vs Without Template Lymph Node Dissection in High-Risk Renal Cell Carcinoma (T-LND RCC)
NCT07321197Renal Cell Carcinoma (Kidney Cancer)
Tianjin Medical University Second Hospital
Not applicable
220
Tianjin
2025-09-01
Recruiting
The Guiding Value of Liquid Biopsy Based on Urinary Tumor DNA/RNA in the Second Transurethral Resection of High-risk Non-muscle Invasive Bladder Cancer
NCT07130578Bladder Cancer, Liquid Biopsy
Tianjin Medical University Second Hospital
Observational
60
Tianjin
2025-09-01
Recruiting
Preoperative Therapy of Super-selective Tumor Artery Embolization Combined With Toripalimab and Axitinib in Advanced RCC
NCT07172386Renal Cell Carcinoma (RCC)
Tianjin Medical University Second Hospital
Phase 2
40
Tianjin
2025-07-31
Recruiting
Neoadjuvant Tislelizumab + Nab-Paclitaxel Followed by Distal Ureterectomy for Ureteral Cancer
NCT07125547Ureteral Cancer, Neoadjuvant Therapy, PD-1 Inhibitor, Kidney-sparing
Tianjin Medical University Second Hospital
Phase 2
35
Tianjin
2025-07-05
Recruiting
Neoadjuvant Tislelizumab in Combination With Nab-Paclitaxel for UTUC
NCT07126119Upper Tract Urothelial Carcinoma, Neoadjuvant Therapy, PD-1 Inhibitor, Nab-paclitaxel
Tianjin Medical University Second Hospital
Phase 2
35
Tianjin
2025-07-05
Recruiting
Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4/19/CCND1)
NCT06895733Solid Tumor, Adult, Next-generation Sequencing, Precision Medicine
Tianjin Medical University Second Hospital
Phase 1/2
65
Tianjin
2024-11-27
Recruiting
Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion
NCT06739395Solid Tumor, Precision Medicine
Tianjin Medical University Second Hospital
Phase 2
300
Tianjin
2024-11-01
Recruiting
RC48 Monotherapy or Combination With Envafolimab for CDK12 Alterations mCRPC With Standard Treatment Failure
NCT06663007Prostate Cancer, CDK12 Gene Mutation
Tianjin Medical University Second Hospital
Phase 1/2
72
Tianjin
2024-09-24
Recruiting
Study on MRD Prediction of Efficacy of Toripalimab in the Treatment of High-risk Recurrent Renal Carcinoma
NCT07657325Renal Cell Carcinoma (RCC)
Tianjin Medical University Second Hospital
Observational
110
Tianjin
2024-04-01
Recruiting
Efficacy and Safety of Tislelizumab in Combination With Disitamab-vedotin as Neoadjuvant Therapy for HER2-positive High-risk Upper Tract Urothelial Carcinoma (UTUC)
NCT05837806Neoadjuvant Immunotherapy
Tianjin Medical University Second Hospital
Phase 2
21
Tianjin
2022-12-30
Active, closed
A Study of Toripalimab in Adjuvant Therapy After Resection of High-risk Renal Cancer
NCT06584435High-risk Renal Cell Carcinoma
Tianjin Medical University Second Hospital
Phase 2
100
Tianjin
2022-10-10
Active, closed
Imaging-Guided Classification for Endophytic Renal Tumors: PN Strategies & Outcomes
NCT06954571Renal Tumors
Tianjin Medical University Second Hospital
Observational
190
Tianjin
2018-01-01
Rows per page Showing 1–25 of 25
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/tianjin

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 25 of those studies with a site in Tianjin that also match the filters currently applied.

How many clinical trials are recruiting in Tianjin?

19 of the 25 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 3 have not yet opened recruitment, 3 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Tianjin), 25 studies
PhaseStudiesRecruitingShare
Phase 2121048%
Not applicable5420%
Observational5320%
Phase 1/2228%
Phase 2/3104%

Most active sponsors

Lead sponsors with the most studies (Tianjin)
Lead sponsorStudiesRecruiting
Tianjin Medical University Second Hospital2519
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.